Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nkarta Therapeutics

Request full access

Nkarta Therapeutics is a biotech company

South San Francisco, United StatesFounded 2015Biotech & Life Sciences

About Nkarta Therapeutics

Nkarta is a biotechnology company focused on developing next-generation cell therapies to treat cancer and autoimmune diseases. Utilizing proprietary NK (natural killer) cell expansion technology pioneered by Dario Campana, Nkarta enhances the pathogen-fighting capabilities of these immune cells to search and destroy tumor cells more effectively. The company operates in the biopharmaceutical market, targeting patients with life-threatening conditions. Nkarta's business model revolves around research and development, clinical trials, and eventual commercialization of its cell therapy products. Revenue is generated through partnerships, licensing agreements, and future product sales. The company serves a diverse range of clients, including healthcare providers, research institutions, and patients. Nkarta aims to improve the efficacy, tolerability, and accessibility of cell therapies, making them more potent and rapidly available to a broad patient population.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020
Employees
159
Open positions
1
Dealroom signal
46.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing Mar 2024 $240M — SR One · Adage Capital · OrbiMed · Janus Henderson Investors ↗
POST IPO EQUITYOther financing Apr 2022 $230M — Undisclosed ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 $0 — −$113M —
2025 $0 — −$113M —
2024 $0 — −$119M —
2023 $0 — −$126M —
2022 $0 — −$119M —
2021 $0 — −$86M —
2020 $0 — −$91M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Nkarta Therapeutics website traffic

Latest recorded traffic for Nkarta Therapeutics is 5.4K monthly website visits, down 16.9% over the last three months. Nkarta Therapeutics's team grew 5.3% over the past year.

Latest monthly visits5.4K 3-month web change-16.9% 1-year team growth+5.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nkarta Therapeutics in the South San Francisco ecosystem

Live from Dealroom

The Nkarta Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Novo Seeds
  • NEA
  • SR One
  • Novo Holdings
  • Samsara BioCapital
  • EQT Life Sciences
  • Amgen Ventures
  • RA Capital Management
  • Logos Capital

Series B and later8 investors entered at this stage

Other known investors1 additional known investor

  • Stanford University
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States98.1%
🇩🇪 Germany0.9%
🇵🇰 Pakistan0.9%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nkarta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nkarta Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.